Legend: Slower-than-expected US earlier-line Carvykti share gain v. competitive myeloma meds, Street views

 

Legend Biotech posts Q3 2026 EPS $0.13 on revenue $359.5M, beats EPS but misses revenue estimates, highlights slower U.S. earlier-line Carvykti uptake

• Carvykti net trade sales $710m, +36% YoY, with US +19% and ex-US +86%.
• EPS $0.13 rose 218% YoY and total revenue grew 32% YoY, while adjusted net income swung to $55.6m profit.
• Legend Biotech's Q3 2026 net income swung to $51.7M during the quarter.
• Gross margin reached 58%, beating prior low-50s expectation; Q4 guided to high-50s.
• Operating margin excluding one-time credit improved to 6% from -16% a year ago.
• Management said Q4 sales consensus sits at the high end of its internal scenarios for Carvykti.
• Company reiterated double-digit 2027 growth and $5B+ peak sales potential for the Carvykti franchise.
• US Carvykti sales were flat sequentially despite earlier-line adoption, reflecting slower-than-hoped share gains.
• Main concern: Slower-than-expected US earlier-line Carvykti share gains versus competitive myeloma therapies and Street expectations.
• Competition from bispecifics and upcoming BCMA CAR-Ts expected to pressure late-line myeloma market share.
• Ex-US growth benefited from new launches across 20 markets and more active treatment centers.
• Management still targets full-year 2026 adjusted profitability, sees substantial global Carvykti growth, citing strong Carvykti revenue, margin upside, disciplined spending.
• FDA cleared IND for in vivo CD19/CD20 CAR-T LB2501, which showed 100% ORR and 100% CR at dose-level two.
• Company holds $853m cash with no long-term debt, supporting pipeline investments and commercial expansion.
• Legend Biotech confirmed Ingrid Zhang as its new company CEO.

https://finviz.com/stock?t=LEGN&p=d